intraven
immunoglobulin
infecti
diseas
back
preantibiot
passiv
prophylaxi
era
jagadeesh
bayri
bastien
lacroixdesmaz
michel
kazatchkin
dramat
increas
number
novel
infecti
agent
resist
antimicrobi
drug
incit
need
adjunct
therapi
war
infecti
diseas
excit
recent
studi
demonstr
use
antibodi
form
intraven
immunoglobulin
ivig
infect
virtu
divers
repertoir
immunoglobulin
possess
wide
spectrum
antibacteri
antivir
specif
ivig
provid
antimicrobi
efficaci
independ
pathogen
resist
repres
promis
altern
strategi
treatment
diseas
specif
therapi
yet
avail
adapt
immun
respons
pathogen
activ
cascad
event
involv
antigenpres
cell
apc
cell
b
cell
ultim
lead
protect
either
humor
cellular
immun
humor
immun
mediat
b
cell
produc
antibodi
contribut
toward
neutral
pathogen
clearanc
vaccin
aim
stimul
adapt
immun
respons
long
term
antigenspecif
manner
use
modifi
inactiv
pathogen
compon
deriv
pathogen
instant
shortterm
protect
infect
achiev
administr
specif
antibodi
passiv
manner
antibiot
antimicrobi
drug
avail
clinic
use
antibodi
passiv
serotherapi
use
treatment
certain
infect
centuri
wit
remark
discoveri
includ
antimicrobi
agent
chang
face
medic
practic
use
antibiot
prevent
vaccin
led
declin
major
endem
industri
countri
lesser
extent
develop
countri
howev
pathogen
develop
resist
antimicrobi
agent
develop
develop
countri
figur
emerg
alarmingli
signific
resist
antimicrobi
agent
pathogen
togeth
recognit
increas
rang
novel
infecti
agent
potenti
threat
biolog
warfar
rekindl
interest
antibodybas
therapi
potenti
adjunct
battl
infecti
diseas
immun
confer
vaccin
depend
condit
host
demand
certain
timefram
respons
wherea
passiv
antibodi
principl
deliv
instant
protect
regardless
immun
statu
host
sever
report
recent
reemphas
potenti
use
antibodi
form
intraven
figur
evolut
infecti
diseas
microbi
resist
optim
gener
dawn
antimicrobi
era
soon
quench
emerg
penicillinresist
staphylococcu
aureu
evolut
increasingli
antimicrobialresist
pathogen
develop
develop
countri
b
stem
multitud
factor
includ
widespread
sometim
inappropri
use
antimicrobi
extens
use
agent
growth
enhanc
anim
feed
rel
eas
antimicrobialresist
bacteria
cross
geograph
barrier
widespread
industri
agricultur
use
indiscrimin
use
antimicrobi
fail
treatment
old
simpl
drug
econom
reason
develop
countri
also
led
sever
diseas
spread
infect
along
conting
select
pressur
lead
emerg
variant
immunoglobulin
ivig
antiinfecti
agent
sever
viral
bacteri
infect
ivig
therapeut
prepar
normal
human
igg
obtain
pool
plasma
thousand
healthi
blood
donor
exposur
donor
uniqu
environ
eg
geographi
endem
infect
vaccin
type
offood
antigen
give
rise
ivig
consist
divers
repertoir
immunoglobulin
molecul
possess
wide
spectrum
antibacteri
antivir
specif
although
specif
hyperimmun
gammaglobulin
avail
applic
limit
specif
pathogen
wherea
advantag
ivig
treatment
infecti
diseas
lie
polyclon
abil
interact
broad
rang
antigen
pathogen
although
number
clinic
trial
use
ivig
prophylact
therapeut
agent
infecti
diseas
limit
tabl
result
variou
vivo
vitro
studi
suggest
ivig
repres
promis
altern
strategi
treatment
diseas
specif
therapi
current
exist
requir
adjunct
treatment
patient
primari
immunodefici
suscept
recurr
infect
respiratori
intestin
tract
caus
haemophilu
influenza
streptococcu
pneumonia
giardia
lamblia
campylobact
jejuni
sinc
immunoglobulin
therapi
introduc
treat
immunodefici
patient
subsequ
standard
dose
ivig
doubl
frequenc
sever
infect
dramat
decreas
recent
multicentr
placebocontrol
trial
provid
support
ivig
efficaci
adjunct
therapi
group
streptococc
toxic
shock
syndrom
stss
trial
demonstr
signific
decreas
sepsisrel
organ
failur
ivigtr
patient
compar
patient
treat
equal
volum
albumin
anoth
studi
prophylact
ivig
shown
reduc
incid
septic
complic
increas
serum
bactericid
activ
small
group
adult
septic
patient
compar
patient
receiv
human
albumin
ivig
prepar
contain
high
antibodi
titr
west
nile
viru
wnv
found
benefici
patient
wnv
enceph
furthermor
experi
mice
suggest
ivig
might
amelior
abort
establish
wnv
infect
howev
patient
death
recent
report
despit
success
clearanc
wnv
nervou
system
use
ivig
anecdot
report
although
inconclus
stimul
interest
offlabel
use
ivig
treat
sever
wnv
diseas
parvoviru
cytomegaloviru
infect
emerg
caus
glomerulopathi
endogen
transplant
kidney
treatment
patient
ivig
kidney
transplant
shown
success
erad
virus
addit
ivig
therapi
led
clearanc
viremia
resolut
symptom
reestablish
cytokin
balanc
patient
chronic
fatigu
syndrom
associ
acut
infect
newli
elucid
human
metapneumoviru
hmpv
import
caus
respiratori
diseas
divers
subpopul
antivir
agent
vaccin
current
approv
treatment
prevent
ivig
ribavirin
found
exert
equival
antivir
activ
hmpv
tissu
culturebas
assay
result
point
clinic
evalu
ivig
alon
combin
ribavirin
undertaken
hmpv
infect
might
prove
effect
agent
efficaci
vaccin
develop
ribavirin
also
use
recent
outbreak
sever
acut
respiratori
syndrom
sar
specif
therapi
avail
ivig
prepar
donor
geograph
locat
sar
outbreak
occur
might
prove
effect
adjunct
therapi
ivig
undoubtedli
magic
bullet
adjunct
treatment
infecti
condit
sever
studi
assess
efficaci
ivig
sepsi
vari
result
ivig
immunocompromis
patient
undergo
cancer
chemotherapi
bone
marrow
transplant
transplant
solid
organ
significantli
reduc
incid
bacteri
sepsi
syndrom
addit
conclus
data
avail
date
support
use
ivig
sepsi
case
except
defin
subgroup
stss
surgic
patient
sever
scoredefin
postop
sepsi
young
patient
meningococc
septic
shock
although
ivig
prophylaxi
treatment
recommend
infant
whose
mother
hepat
measl
poliomyel
infect
near
time
parturit
possibl
indic
infecti
diseas
prophylaxi
remain
specul
ivig
fail
reduc
incid
hospitalacquir
infect
prematur
lowbirthweight
infant
multipl
studi
conduct
past
year
suggest
ivig
treatment
margin
use
prevent
treatment
seriou
neonat
infect
henc
prophylact
use
ivig
prevent
neonat
nosocomi
infect
discourag
although
substanti
differ
might
found
among
ivig
prepar
batch
eg
neutral
antibodi
level
streptococci
wnv
studi
evalu
clinic
efficaci
differ
ivig
prepar
yield
equivoc
result
protect
addit
suffici
amount
antibodi
frequent
isol
bacteri
antigen
achiev
patient
despit
quantit
differ
batch
prepar
ivig
howev
signific
differ
ivig
prepar
prevent
sinopulmonari
infect
observ
studi
impli
ivig
prepar
batch
equal
thu
highlight
need
larger
compar
studi
identifi
standard
optim
treatment
princip
compon
ivig
natur
antibodi
nab
igg
isotyp
nab
virtu
reactiv
pathogen
host
receptor
long
recogn
block
delay
infect
cell
microb
nab
enhanc
recruit
viru
lymphoid
organ
present
b
cell
therebi
elicit
activ
immun
respons
concert
complement
nab
act
endogen
adjuv
gener
vaccineinduc
protect
tcell
respons
inde
antibodi
within
ivig
direct
chemokin
receptor
shown
block
infect
hiv
vitro
antibodi
ivig
enhanc
opson
thu
promot
phagocytosi
antibodymedi
cellular
cytotox
figur
furthermor
ivig
shown
stimul
product
virusspecif
igg
concomit
increas
level
interleukin
cytokin
import
immunoglobulin
class
switch
process
b
cell
produc
differ
class
antibodi
specif
indic
progress
immun
respons
protect
effect
ivig
infect
attribut
abil
specif
antibodi
neutral
pathogen
bacteri
toxin
ivig
prepar
contain
antibodi
larg
varieti
pathogen
could
relat
exposur
donor
contribut
ivig
prepar
infect
vaccin
exampl
ivig
prepar
isra
donor
contain
high
titr
wnv
result
endem
natur
wnv
infect
popul
contrast
north
american
ivig
prepar
contain
detect
wnv
antibodi
abil
neutral
wide
varieti
superantigen
facilit
opson
streptococci
ivig
suggest
potenti
adjunct
therapi
stss
invas
group
streptococci
iga
signific
increas
plasma
neutral
activ
superantigen
express
autolog
streptococci
observ
patient
iga
follow
ivig
treatment
recent
report
suggest
neutral
antiinterferon
gamma
autoantibodi
favour
recurr
infect
intracellular
pathogen
might
open
novel
prospect
ivig
therapi
owe
high
content
antiidiotyp
ivig
neutral
downregul
synthesi
autoantibodi
b
cell
express
relev
idiotyp
despit
use
ivig
infecti
diseas
year
sever
fundament
question
remain
unansw
includ
appropri
clinic
indic
optim
dosag
frequenc
administr
first
step
toward
therapeut
util
ivig
infecti
diseas
would
finetun
dose
regimen
clinic
trial
high
dose
case
autoimmun
condit
ivig
inhibit
function
differ
arm
immun
system
includ
inhibit
matur
function
dendrit
cell
attenu
tcell
prolifer
product
proinflammatori
cytokin
therefor
highdos
regimen
might
appropri
treatment
infecti
diseas
common
rout
infus
ivig
intraven
rout
howev
one
might
consid
altern
rout
administr
depend
type
infect
viral
enceph
administr
intraventricular
intrathec
rout
might
prove
benefici
first
h
intraven
infus
ivig
serum
igg
level
high
concentr
igg
cerebrospin
fluid
csf
increas
much
twofold
return
normal
within
one
week
degre
penetr
csf
intraven
rout
unpredict
altern
rout
ivig
administr
sought
topic
immunotherapi
promis
approach
epitheli
infect
intranas
ivig
immunotherapi
pneumonia
effect
mice
pneumonia
fail
prevent
bacteremia
probabl
short
halflif
intranas
administ
ivig
sever
barrier
includ
geometri
airway
enhanc
clearanc
surfact
enzym
alveolar
macrophag
might
hinder
effici
deliveri
ivig
respiratori
tract
attempt
enhanc
halflif
ivig
intranas
rout
use
liposom
formul
unsuccess
combin
therapi
synergist
therapeut
efficaci
ivig
report
combin
antibiot
chemotherapi
combin
therapi
might
achiev
effect
antiinfect
therapi
certain
pathogen
strain
therebi
reduc
risk
select
resist
variant
geograph
region
endem
specif
diseas
select
donor
entir
world
rather
select
region
prepar
ivig
might
advantag
particularli
infecti
diseas
altern
approach
would
prepar
tailormad
ivig
made
plasma
pool
donor
endem
region
complement
human
mous
monoclon
antibodi
hyperimmun
gammaglobulin
assess
antipathogen
activ
identif
specif
neutral
antimicrobi
activ
ivig
would
help
determin
therapeut
potenti
infecti
diseas
antipathogen
elisa
enzymelink
immunosorb
assay
titr
alon
sometim
mislead
complement
function
assay
ivig
safe
effect
treat
sever
human
diseas
use
approv
patient
antibodi
defici
broad
rang
autoimmun
inflammatori
disord
howev
infecti
diseas
belong
group
current
approv
medic
indic
differ
scheme
use
sever
studi
render
interpret
result
difficult
howev
enough
encourag
experiment
clinic
data
maintain
continu
interest
ivig
field
demand
studi
infecti
condit
ivig
found
benefici
uncontrol
studi
ie
lack
placebocontrol
clinic
trial
control
trial
particularli
viral
diseas
certain
defin
septic
subgroup
ivig
repres
promis
unproven
treatment
imper
evid
howev
ivig
prepar
must
contain
function
activ
optim
amount
antigenspecif
antibodi
effect
ivig
prepar
compar
thoroughli
effici
advers
event
accord
regulatori
guidelin
ivig
product
test
steril
puriti
pyrogen
safeti
howev
strict
requir
exist
concern
concentr
specif
antibodi
research
requir
understand
mechan
action
ivig
infecti
diseas
rel
role
function
antibodi
within
ivig
